BioSpace News Archive

Ra Medical Systems, Inc. (NYSE: RMED), a medical device company focusing on commercializing excimer laser systems to treat vascular and dermatological diseases, today reported certain preliminary results for the quarter ended June 30, 2019, as well as a leadership transition.

VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”) today announced financial results and a business update for the second quarter ended June 30, 2019

Intends to retire from the Board at the expiration of his current term in June 2020.

The Company intends to release its preliminary revenue and to file an 8-K/A including pro forma financials associated with its acquisition of Ross Optical Industries

Signant Health ( HYPERLINK “http://www.signanthealth.com” signanthealth.com), a leading provider of technology for clinical research, today launches the Signant Health Partner Program, a significant investment the company is making to enable clinical research organizations (CROs) to better serve sponsors in the areas of Patient Data, Patient Experience, Clinical Supplies, and Endpoint Quality Solutions

Harvard, Merck to collaborate on research led by Harvard immunologist Arlene Sharpe, seeking to identify new pathways for the treatment of cancer

Prometic Life Sciences Inc. announced financial results for its fiscal 2019 second quarter ended June 30th 2019.

Propanc Discusses Next Steps for Promising Research Collaboration with University of Jaén and Granada to Further Optimize Quality, Safety and Performance of PRP

Millendo Therapeutics, Inc. (Nasdaq: MLND), a clinical-stage biopharmaceutical company primarily focused on developing novel treatments for orphan endocrine diseases with significant unmet needs, today provided a corporate update and reported financial results for the quarter ended June 30, 2019.

Soliton, Inc., (Nasdaq: SOLY) (“Soliton” or the “Company”), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center (“MD Anderson”), today announced that the Company has initiated patient recruitment for its upcoming pivotal cellulite trial across all four trial sites.